Parkinson’s Disease

Parkinson’s disease is a disorder of the nervous system, with primary symptoms including tremor, stiffness in the limbs and difficulty with walking and balance. The symptoms worsen as the disease progresses, affecting the patient’s quality of life adversely. Parkinson’s disease, which presents itself when the dopaminergic neurons in the brain, is the second most common neurodegenerative disorder globally after Alzheimer’s disease. Although Parkinson’s disease is generally seen in people over the age of 60, younger people may have early-onset forms, which are often inherited.

In the advanced stages of the disease, the patient may experience difficulty walking and speaking, and become unable to perform simple daily tasks. Even though this progressively degenerative disease does not have a known cure yet, some of its symptoms may be alleviated with certain medicines or a device that is surgically planted in the brain.


Earstim is a wearable medical device that may alleviate Parkinson’s disease symptoms such as tremors, slowness, and stiffness without a surgical procedure. The primary aim of Earstim is to maximize the quality of life in Parkinson’s patients. The user-friendly wearable device, which may reduce dependency on medications and has the potential to be used as an aid in addition to prescribed medications, enhances the patient’s comfort. The device is in the development stage and new features continue to be added. Upon obtaining the required certifications, Earstim is expected to be available for patient use within two years.

Key Features


No surgical procedure required.


Ergonomically designed for easy wearing and removal.


Short-term effect proven; no side effects observed.


Intellectual rights protected.

User Friendly

Chargeable for daylong use.


Stoparkinson currently holds four patent families and continues to expand the scope of its intellectual rights portfolio. Earstim has already been patented in the USA, Canada, the UK, Turkey, Israel, France, Germany, Belgium, the Netherlands, Sweden, Italy, Spain, Switzerland, Austria, Poland, Romania, Russia, Korea, China, and Japan.

Clinical Trials

Pivot Clinical Trial

Dosage Determination Study

Presubmission meeting with FDA


Motion Capture Analysis Research

Mechanism of Action Study

Proof of Concept Study

About Us

Earstim was designed as a wearable medical device to alleviate the symptoms of Parkinson’s disease, and with clinical trials initiated in 2016, steps were quickly taken for its development. Following the positive results in the proof of concept study and other clinical trials, the decision was made for incorporation of a company. Stoparkinson Healthcare Systems, LLC, a company incorporated in 2019 in the USA, continues to work on the commercialization of Earstim.



PSG 32nd Annual Meeting

Stoparkinson attended the Parkinson Study Group 32nd annual meeting in Phoenix, Arizona. We presented the U.S. pilot study preliminary results. We got great attention from key opinion leaders.

Motion Capture Analysis article published

The results of the research on the effects of Earstim on the motor skills of Parkinson’s patients were published in an article in October 2020 in the Frontiers in Human Neuroscience journal. Please click here to access the article.

Critical presubmission meeting with FDA

A presubmission meeting was held with the FDA officials in February 2020 at the Administration’s offices to discuss the use of Earstim in clinical trials in the USA and its commercialization.